AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Reserve Bank casts shadow over NZ sharemarket
Markets Market close

Reserve Bank casts shadow over NZ sharemarket

After a strong start, the sharemarket dipped following the RBNZ's MPS.

Fisher & Paykel ups pre-Christmas dividend
Markets

Fisher & Paykel ups pre-Christmas dividend

And employees will get a share of $4 million.

ERoad half-year earnings reflect straighter steering
Markets

ERoad half-year earnings reflect straighter steering

Cash burn under control, strong potential in North America.

Ben Moore 11:10am
Ryman Healthcare cites ‘challenging’ housing market in 4pc net profit drop
Markets

Ryman Healthcare cites ‘challenging’ housing market in 4pc net profit drop

New Zealand’s largest listed retirement company cited the “challenging” housing market in declaring net profit down 4% and downgrading its profit outlook.Ryman Healthcare’s reported net profit after tax fell 4% from $193 million a year ago to $186.7m for the six months to Sept 30...